Any biosimilar manufacturer will tell you that one of the most daunting and delaying issues in biosimilar development is the abuse of the patent system by reference manufacturers. They delay launch by years, resulting in billions in additional revenues for the reference product, and extra workload for the courts. At last week’s GRx+Biosims meeting, panelists … Continue reading The Sad State of Patent Affairs: Legislative Help on the Way?